Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.
ADVANCED SEARCH
Log in
Top
European Archives of Oto-Rhino-Laryngology
Published in: European Archives of Oto-Rhino-Laryngology 11/2015

01-11-2015 | Head and Neck

Assessment of caroverine as a potential chemotherapeutical agent in HNSCC cell lines

Authors: Georg Haymerle, Dietmar Thurnher, Lorenz Kadletz, Isabella Stanisz, Markus Brunner, Ulana Kotowski, Elisabeth Enzenhofer, Gregor Heiduschka

Published in: European Archives of Oto-Rhino-Laryngology | Issue 11/2015

Login to get access

Abstract

Since the prognosis of head and neck squamous cell carcinoma (HNSCC) still remains poor, identifying novel chemotherapeutic agents is of outmost importance. The anticancer potential of quinoxalines has been described in various tumor entities. Caroverine, also a quinoxaline derivative, has been shown to suppress tumor promotion factors. The aim of this study was to evaluate the effect of caroverine on HNSCC cell lines. The HNSCC cell lines SCC9, SCC25, CAL27, and FaDu were incubated with caroverine alone or in combination with cisplatin, 5-fluorouracil (5-FU) or cetuximab. Cell viability was measured using the CCK-8 assay. The murine 3T3 fibroblast cell line was used to address tissue specificity. Apoptosis was visualized by immunohistochemistry. Caroverine showed a dose-dependent growth inhibition in all cell lines, IC50 values ranged from 75.69 to 179.80 µM. This effect was increased when caroverine was combined with cetuximab or 5-FU. Immunohistochemistry displayed more apoptosis after caroverine treatment compared to controls. Furthermore, caroverine alone had no growth inhibitory effect on 3T3 cells. For the first time, this study provides evidence that caroverine may serve as a supportive drug in the treatment of HNSCC patients.
Literature
1.
Jemal A, Bray F, Center MM, Ferlay J, Ward E, Forman D (2011) Global cancer statistics. CA Cancer J Clin 61:69–90CrossRefPubMed
2.
Leemans CR, Braakhuis BJM, Brakenhoff RH (2011) The molecular biology of head and neck cancer. Nat Rev Cancer 11:9–22CrossRefPubMed
3.
Moarbess G, Deleuze-Masquefa C, Bonnard V et al (2008) In vitro and in vivo anti-tumoral activities of imidazo[1,2-a]quinoxaline, imidazo[1,5-a]quinoxaline, and pyrazolo[1,5-a]quinoxaline derivatives. Bioorg Med Chem 16:6601–6610CrossRefPubMed
4.
Ingle R, Marathe R, Magar D, Patel HM, Surana SJ (2013) Sulphonamido-quinoxalines: search for anticancer agent. Eur J Med Chem 65:168–186CrossRefPubMed
5.
Udilova N, Kozlov AV, Bieberschulte W, Frei K, Ehrenberger K, Nohl H (2003) The antioxidant activity of caroverine. Biochem Pharmacol 65:59–65CrossRefPubMed
6.
Nohl H, Bieberschulte W, Dietrich B, Udilova N, Kozlov AV (2003) Caroverine, a multifunctional drug with antioxidant functions. BioFactors 19:79–85CrossRefPubMed
7.
König P, Conca A, Lugmayer B (1999) Does a glutamate receptor blocker (Caroverine) enhance haloperidol in the treatment of schizophrenia? Neuropsychobiology 40:140–141CrossRefPubMed
8.
Saletu B, Grünberger J, Anderer P, Linzmayer L, König P (1995) Acute central effects of the calcium channel blocker and antiglutamatergic drug caroverine. Double-blind, placebo-controlled, EEG mapping and psychometric studies after intravenous and oral administration. Arzneimittelforschung 45:217–229PubMed
9.
Nohl H, Rohr-Udilova N, Gille L, Bieberschulte W, Jurek D, Marian B, Schulte-Hermann R (2005) Ubiquinol and the papaverine derivative caroverine prevent the expression of tumour- promoting factors in adenoma and carcinoma colon cancer cells induced by dietary fat. BioFactors 25:87–95CrossRefPubMed
10.
Tsuruo T, Iida H, Tsukagoshi S, Sakurai Y (1982) Increased accumulation of vincristine and adriamycin in drug-resistant P388 tumor cells following incubation with calcium antagonists and calmodulin inhibitors. Cancer Res 42:4730–4733PubMed
11.
Heiduschka G, Lill C, Schneider S et al (2014) The effect of cilengitide in combination with irradiation and chemotherapy in head and neck squamous cell carcinoma cell lines. Strahlenther Onkol 190:472–479CrossRefPubMed
12.
Heiduschka G, Erovic BM, Vormittag L et al (2009) 7beta-hydroxycholesterol induces apoptosis and regulates cyclooxygenase 2 in head and neck squamous cell carcinoma. Arch Otolaryngol Head Neck Surg 135:261–267CrossRefPubMed
13.
Denk DM, Heinzl H, Franz P, Ehrenberger K (1997) Caroverine in tinnitus treatment. A placebo-controlled blind study. Acta Otolaryngol 117:825–830CrossRefPubMed
14.
Domeisen H, Hotz MA, Häusler R (1998) Caroverine in tinnitus treatment. Acta Otolaryngol 118:606–608CrossRefPubMed
15.
Geretsegger C, Fartacek R (1998) Infusional high-dose application of the calcium-channel-blocking and antiglutamatergic agent caroverine in the treatment of alcohol withdrawal (DSM-III-R 291.80). Eur Neuropsychopharmacol 8:191–194CrossRefPubMed
16.
Rodrigues FAR, Bomfim IDS, Cavalcanti BC et al (2014) Design, synthesis and biological evaluation of (E)-2-(2-arylhydrazinyl)quinoxalines, a promising and potent new class of anticancer agents. Bioorg Med Chem Lett 24:934–939CrossRefPubMed
17.
Lee SH, Kim N, Kim SJ, Song J, Gong YD, Kim SY (2013) Anti-cancer effect of a quinoxaline derivative GK13 as a transglutaminase 2 inhibitor. J Cancer Res Clin Oncol 139:1279–1294CrossRefPubMed
18.
Ghattass K, El-Sitt S, Zibara K, Rayes S, Haddadin MJ, El-Sabban M, Gali-Muhtasib H (2014) The quinoxaline di-N-oxide DCQ blocks breast cancer metastasis in vitro and in vivo by targeting the hypoxia inducible factor-1 pathway. Mol Cancer 13:12PubMedCentralCrossRefPubMed
19.
Chaturvedi NK, Rajule RN, Shukla A et al (2013) Novel treatment for mantle cell lymphoma including therapy-resistant tumor by NF-κB and mTOR dual-targeting approach. Mol Cancer Ther 12:2006–2017PubMedCentralCrossRefPubMed
20.
Palanichamy K, Sreejayan N, Ontko AC (2012) Overcoming cisplatin resistance using gold(III) mimics: anticancer activity of novel gold(III) polypyridyl complexes. J Inorg Biochem 106:32–42CrossRefPubMed
Metadata
Title
Assessment of caroverine as a potential chemotherapeutical agent in HNSCC cell lines
Authors
Georg Haymerle
Dietmar Thurnher
Lorenz Kadletz
Isabella Stanisz
Markus Brunner
Ulana Kotowski
Elisabeth Enzenhofer
Gregor Heiduschka
Publication date
01-11-2015
Publisher
Springer Berlin Heidelberg
Published in
European Archives of Oto-Rhino-Laryngology / Issue 11/2015
Print ISSN: 0937-4477
Electronic ISSN: 1434-4726
DOI
https://doi.org/10.1007/s00405-014-3364-0

Other articles of this Issue 11/2015

European Archives of Oto-Rhino-Laryngology 11/2015 Go to the issue

Head and Neck

Combined use of gastric pull-up and pectoralis major flaps for massive defects after total laryngopharyngoesophagectomy in patients with advanced hypopharyngeal carcinoma

Head and Neck

Prospective clinical study on long-term swallowing function and voice quality in advanced head and neck cancer patients treated with concurrent chemoradiotherapy and preventive swallowing exercises

Head and Neck

Non-endemic locoregionally advanced nasopharyngeal carcinoma: long-term outcome after induction plus concurrent chemoradiotherapy in everyday clinical practice

Otology

Microanatomy of the tympanic membrane in chronic myringitis obtained with optical coherence tomography

Laryngology

Endoscopic epiglottopexy using Lichtenberger’s needle carrier to avoid breakdown of repair

Laryngology

The effect of antireflux surgery on laryngeal symptoms, findings and voice parameters